ReviewInternational journal of women's health2022
Reviewing Accuracy of First Trimester Screening for Preeclampsia Using Maternal Factors and Biomarkers.
Review in International journal of women's health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- First Trimester Screening for Preterm Preeclampsia in the United Kingdom: A Cost-Effectiveness Analysis.BJOG : an international journal of obstetrics and gynaecology · 2026Article
- Improving Clinical Outcomes Related to Preeclampsia: Real-World Impacts of Implementation of a Redesigned Approach to Antenatal Care-The Initial Maternity Assessment and Planning (IMAP) Service.The Australian & New Zealand journal of obstetrics & gynaecology · 2026Article
- Smartphone-based preeclampsia diagnosis through detection of dual biomarkers - nephrin and podocalyxin.Biosensors & bioelectronics · 2026Article
- Comparison of Machine Learning Models and the FMF Competing-Risks Algorithm for First-Trimester Preeclampsia Screening in a Romanian Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- World Pre-eclampsia Day: are we moving in the right direction?Singapore medical journal · 2026Article
- Machine Learning for Dynamic and Short-Term Prediction of Preeclampsia Using Routine Clinical Data.JAMA network open · 2026Article
- Pathologic abnormalities of deep placentation in the great obstetrical syndromes: Implications for understanding the pathophysiology, risk assessment in early pregnancy, and personalized prevention.Journal of reproductive immunology · 2026Review
- Exploring the Relevance of S100A8 and S100A9 Proteins in Preeclampsia: A Narrative Review.International journal of molecular sciences · 2025Review
- Novel biomarkers for preeclampsia: Promises and pitfalls.Current opinion in obstetrics & gynecology · 2025Review
- Utility of the US Preventive Services Task Force for Preeclampsia Risk Assessment and Aspirin Prophylaxis.JAMA network open · 2025Observational
- Prediction of pre-eclampsia using maternal hemodynamic parameters at 12 + 0 to 15 + 6 weeks.Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2025Article
- Unraveling the gut microbiota-SCFAs-cathepsin C pathway in preeclampsia: a novel therapeutic target.Frontiers in immunology · 2025Article
- Evaluation of Risk Factor Screening Using the Ministry of Health's Scoring System for the Incidence of Early-Onset Preeclampsia in Primary Health Service.International journal of women's health · 2025Article
- Lateral Flow Assay for Preeclampsia Screening Using DNA Hairpins and Surface-Enhanced Raman-Active Nanoprobes Targeting hsa-miR-17-5p.Biosensors · 2024Article
- Multi-centre deep learning for placenta segmentation in obstetric ultrasound with multi-observer and cross-country generalization.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia is a common and important complication of pregnancy, one with potentially significant morbidity and even mortality to both mother and baby. Identifying those at high risk of developing the condition is helpful as there is evidence that the incidence of preeclampsia can be reduced with low dose aspirin taken in pregnancy. Accurately predicting the risk of preeclampsia allows for more targeted aspirin prophylaxis and a greater opportunity for early detection of maternal and/or fetal complications associated with impaired placentation through a schedule of enhanced antenatal surveillance. Traditional preeclampsia prediction models use maternal characteristics and risk factors and have been shown to be of low predictive value. Multiparametric screening tests combine patient characteristics with serum biomarkers and ultrasound Doppler indices and have been shown to be more effective at detecting those at high risk of preeclampsia - more specifically, early-onset preeclampsia (onset of preeclampsia <34 weeks' gestation). Multiparametric screening has now been validated in different populations. The true cost effectiveness of a multiparametric screening model for preeclampsia screening is not yet fully known and will vary depending on the clinical setting. Despite the growing body of evidence for its improved detection rates, first trimester preeclampsia screening using multiparametric models is not widely implemented and is not part of the recommendations for antenatal screening from most international bodies. The International Federation of Gynecology and Obstetrics has advised universal preeclampsia screening using maternal risk factors and biomarkers and has strongly encouraged its promotion worldwide. Various barriers to implementation must be considered such as the immediate cost of equipment and training, the need for audit and quality control, and the expected benefit to the population. Low to middle income settings may require a pragmatic approach to the implementation of multiparametric screening given limited resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.